Pure Global
NCT01841619

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus
University of California, Irvine·Early Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
IVIg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of California, Irvine
Location
Irvine,Irvine, United States of America
Timeline & enrollment
Phase
Early Phase 1
Start date
Mar 01, 2013
End date
Nov 01, 2014
Enrollment
16 participants
Primary outcome

Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS),Skindex 29

Summary

The purpose of this research study is to show that non-steroidal treatment with intravenous
 immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous
 lupus erythematosis (CLE) patients.

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01841619
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01841619 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by University of California, Irvine and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.